{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:17:21Z","timestamp":1792289841374,"version":"4.4.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Supp 1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,1]]},"DOI":"10.1097\/01.mcg.0000145494.76305.11","type":"journal-article","created":{"date-parts":[[2005,1,25]],"date-time":"2005-01-25T18:33:44Z","timestamp":1106678024000},"page":"S3-S8","source":"Crossref","is-referenced-by-count":91,"title":["Hematologic Side Effects of Interferon and Ribavirin Therapy"],"prefix":"10.1097","volume":"39","author":[{"given":"Kris V","family":"Kowdley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210509","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1086\/376971","article-title":"Hematologic disorders associated associated with hepatitis C virus infection and their management.","volume":"37","author":"Dieterich","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"Suppl","key":"R2-2-20210509","first-page":"368A","article-title":"Changes in hemoglobin during therapy with interferon ALFA-2B plus ribavirin in IFN-naive and experienced patients.","volume":"32","author":"Sulkowski","year":"2000","journal-title":"Hepatology"},{"key":"R3-2-20210509","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1365-2893.2004.00490.x","article-title":"Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection.","volume":"11","author":"Sulkowski","year":"2004","journal-title":"J Viral Hepatol"},{"key":"R4-2-20210509","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1046\/j.1365-2036.2002.01326.x","article-title":"Meta-analysis: ribavirin-induced haemolytic anaemia in patients with chronic hepatitis C.","volume":"16","author":"Chang","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"R5-2-20210509","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1053\/gast.1996.v111.pm8898645","article-title":"Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C.","volume":"111","author":"Lai","year":"1996","journal-title":"Gastroenterology"},{"key":"R6-2-20210509","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"R7-2-20210509","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"R9-2-20210509","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1046\/j.1365-2036.2002.01316.x","article-title":"Non-transferrin-bound iron in untreated and ribavirin-treated chronic hepatitis C patients.","volume":"16","author":"Van Vlierberghe","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"R10-2-20210509","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0009-8981(99)00194-1","article-title":"Fast determination of haptoglobin phenotype and calculation of hemoglobin binding capacity using high pressure gel permeation chromatography.","volume":"291","author":"Delanghe","year":"2000","journal-title":"Clin Chim Acta"},{"key":"R11-2-20210509","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1046\/j.1524-4733.2001.45075.x","article-title":"Management strategies for ribavirin-induced hemolytic anemia in the treatment of chronic hepatitis C: Clinical and economic implications.","volume":"4","author":"Devine","year":"2001","journal-title":"Value Health"},{"key":"R12-2-20210509","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1053\/he.2000.5789","article-title":"Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage.","volume":"31","author":"De Franceschi","year":"2000","journal-title":"Hepatology"},{"key":"R13-2-20210509","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/hep.20208","article-title":"Low membrane protein sulfhydrils but not G6PD deficiency predictribavirin-induced hemolysis in hepatitis C.","volume":"39","author":"Grattagliano","year":"2004","journal-title":"Hepatology"},{"key":"R14-2-20210509","first-page":"1192","article-title":"Do antioxidants ameliorate ribavirin related anemia in HCV patients?","volume":"116","author":"Brass","year":"1999","journal-title":"Gastroenterology"},{"key":"R15-2-20210509","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1046\/j.1365-2893.2003.00475.x","article-title":"Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia.","volume":"11","author":"Lindahl","year":"2004","journal-title":"J Viral Hepatol"},{"key":"R16-2-20210509","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0041-008X(84)90139-X","article-title":"Hematological and bone marrow effects of ribavirin in rhesus monkeys.","volume":"74","author":"Canonico","year":"1984","journal-title":"Toxicol Appl Pharmacol"},{"key":"R17-2-20210509","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S0168-8278(01)00029-0","article-title":"BASL Steering Committee: factors influencing ribavirin-induced hemolysis.","volume":"34","author":"Van Vlierbergh","year":"2001","journal-title":"J Hepatol"},{"key":"R18-2-20210509","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3109\/08860229109022152","article-title":"Investigations on the subclinical and clinical nephrotoxicity of interferon alpha-2B in patients with myeloproliferative syndromes.","volume":"13","author":"Kurschel","year":"1991","journal-title":"Renal Failure"},{"key":"R19-2-20210509","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1200\/JCO.1995.13.9.2401","article-title":"Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia.","volume":"13","author":"Sacchi","year":"1995","journal-title":"J Clin Oncol"},{"key":"R20-2-20210509","first-page":"1310","article-title":"Interferon-alpha induced apoptosis in human erythroid progenitors.","volume":"23","author":"Tarumi","year":"1995","journal-title":"Exp Hematol"},{"key":"R21-2-20210509","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1046\/j.1365-2141.2003.04650.x","article-title":"Intracellular signal transduction of interferon on the suppression of haematopoietic progenitor cell growth.","volume":"123","author":"Kato","year":"2003","journal-title":"Br J Haematol"},{"key":"R22-2-20210509","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1053\/jhep.2002.36502","article-title":"Neutropenia during combination therapy of interferon alfa and ribavirin forchronic hepatitis C.","volume":"36","author":"Soza","year":"2002","journal-title":"Hepatology"},{"key":"R23-2-20210509","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1046\/j.1365-2141.2000.02132.x","article-title":"HCV-associated thrombocytopenia: clinical characteristics and platelet response after recombinant alpha2b-interferon therapy.","volume":"110","author":"Garcia-Suarez","year":"2000","journal-title":"Br J Haematol"},{"issue":"Suppl 1","key":"R24-2-20210509","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.gtc.2003.12.003","article-title":"Adherence to combination therapy: influence on sustained virologic response and economic impact.","volume":"33","author":"Manns","year":"2004","journal-title":"Gastroenterol Clin North Am"},{"key":"R25-2-20210509","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1053\/gast.2002.35950","article-title":"International Hepatitis Interventional Therapy Group: adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.","volume":"123","author":"McHutchison","year":"2002","journal-title":"Gastroenterology"}],"container-title":["Journal of Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/01.mcg.0000145494.76305.11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T13:35:07Z","timestamp":1785850507000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00004836-200501001-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1]]},"references-count":24,"journal-issue":{"issue":"Supp 1","published-print":{"date-parts":[[2005]]}},"URL":"https:\/\/doi.org\/10.1097\/01.mcg.0000145494.76305.11","relation":{},"ISSN":["0192-0790"],"issn-type":[{"value":"0192-0790","type":"print"}],"subject":[],"published":{"date-parts":[[2005,1]]}}}